Absci (NASDAQ: ABSI) revenue
Absci reported revenue of $2.8m for fiscal 2025, 38.2% less than in fiscal 2024 ($4.5m). Since fiscal 2020 its revenue has fallen by 41.4%, an average decline of 10.1% a year.
Absci's revenue has fallen for 3 years in a row, and its best year of the last 6 was fiscal 2022. The biggest drop was in fiscal 2025, −38.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $2.8m | −38.2% | −$120.3m | −4,297.0% |
| 2024 | $4.5m | −20.7% | −$108.9m | −2,401.6% |
| 2023 | $5.7m | −0.5% | −$115.5m | −2,020.2% |
| 2022 | $5.7m | +20.2% | −$106.8m | −1,857.5% |
| 2021 | $4.8m | 0.0% | −$75.2m | −1,573.4% |
| 2020 | $4.8m | — | −$13.3m | −278.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Absci revenue compared with its sector
By revenue for its latest fiscal year, Absci ranks 390th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Absci, −38.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 388th | Onkure Therapeutics | $3.4m | 70.9% |
| 389th | Upstream Bio | $2.9m | 20.4% |
| 390th | Absci | $2.8m | −38.2% |
| 391st | Cartesian Therapeutics | $2.8m | −92.8% |
| 392nd | Allogene Therapeutics | $2.6m | 2,500.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Absci
- How much revenue did Absci make in fiscal 2025?
- Absci reported revenue of $2.8m for fiscal 2025, compared with $4.5m in fiscal 2024.
- How much has the revenue of Absci fallen?
- Between fiscal 2020 and fiscal 2025 it went from $4.8m to $2.8m: 41.4% less, an average decline of 10.1% a year.
- What was the best year for revenue at Absci?
- Of its last 6 fiscal years, fiscal 2022, with $5.7m.
- Where does Absci rank in its sector by revenue?
- It ranks 390th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Absci come from?
- From the annual report (Form 10-K) that Absci files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Absci files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Absci: the Absci page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.